septerna novo nordisk

Order byBest matchMost fresh

Novo Nordisk Inks A Major Obesity Deal

Top News

Impacts

Novo Nordisk and Septerna Strike $2.2 Billion Deal to Develop Obesity Pills

The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other cardiometabolic diseases.

· 15h · on MSN

· 1d · on MSN

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

· 1d

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

Under the terms of the agreement, Septerna is eligible to receive around $2.2 billion from Novo Nordisk, including over $200 million in upfront and near-term milestone payments.

· 15h

Ignore The Noise - Novo Nordisk Is A Clear Buy

STAT · 1d

Novo Nordisk strikes deal with Septerna to develop obesity pills

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral Small Molecule PTH1R Agonist to Accelerate Toward the Clinic Later in 2025 Expect to Initiate Phase 1 Trial for SEP-631,

pharmaphorum1d

Novo makes fresh obesity play with $2.2bn Septerna deal

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic diseases, as it pays $200 million for rights to preclinical-stage candidates developed by Septerna.